Back to Journals » OncoTargets and Therapy » Volume 9

Sequential measurements of serum matrix metalloproteinase 9 to monitor chemotherapy responses in patients with advanced non-small-cell lung cancer

Authors Qiao X, Zhai X, Wang J, Zhao X, Yang X, Lv J, Ma L, Zhang L, Wang Y, Zhang S, Yue W

Received 12 December 2015

Accepted for publication 9 March 2016

Published 1 June 2016 Volume 2016:9 Pages 3299—3305


Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Lucy Goodman

Peer reviewer comments 2

Editor who approved publication: Professor Min Li

Xiaojuan Qiao,1–3,* Xiaoran Zhai,1,2,* Jinghui Wang,4 Xiaoting Zhao,1,2 Xinjie Yang,4 Jialin Lv,4 Li Ma,1,2 Lina Zhang,1,2 Yue Wang,1,2 Shucai Zhang,4 Wentao Yue1,2

1Department of Cellular and Molecular Biology, Beijing Chest Hospital, Capital Medical University, 2Department of Cellular and Molecular Biology, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, 3Health Care Ward, The First Hospital Affiliated to Inner Mongolia Medical University, Hohhot, 4Department of Medical Oncology, Beijing Chest Hospital, Capital Medical University, Beijing, People’s Republic of China

*These authors contributed equally to this work

Background: Matrix metalloproteinase 9 (MMP-9) plays an important role in tumor invasion and metastasis, including lung cancer. However, whether variations in serum MMP-9 levels can serve as a biomarker for monitoring chemotherapy curative effect remains unclear. This study was designed to investigate the association between variations in serum MMP-9 levels and chemotherapy curative effect in patients with lung cancer.
Patients and methods: A total of 82 patients with advanced lung cancer were included. All newly diagnosed patients were treated with platinum-based doublet chemotherapy. Serial measurements of serum MMP-9 levels were performed by enzyme-linked immunosorbent assay. In this manner, we chose four time points to examine the association, including before chemotherapy, and 3 weeks after the beginning of the first, second, and fourth cycles of chemotherapy.
Results: Compared with the serum level of MMP-9 before progressive disease, patients with progressive disease had elevated serum levels of MMP-9. Compared with the previous time point of collecting specimens, the serum levels of MMP-9 in the patients with a complete response/partial response/stable disease decreased or were maintained stable. The differences of variation in serum MMP-9 levels in patients with different chemotherapy curative effects were all statistically significant after one cycle, two cycles, and four cycles (after one cycle: P<0.001; after two cycles: P<0.001; after four cycles: P=0.01). However, patients with small-cell lung cancer did not exhibit similar test results.
Conclusion: The variation in serum MMP-9 levels in patients with non-small-cell lung cancer during chemotherapy was closely related to chemotherapy curative effect and could be useful to monitor chemotherapy curative effect for a small portion of patients.

Keywords: prognosis, lung adenocarcinoma, lung squamous carcinoma, chemotherapy, treatment monitoring

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]